Female-specific issues in multiple sclerosis

References

• Kantarci O, Wingerchuk D. Epidemiology and natural history of multiple sclerosis: new insights. Curr. Opin. Neurol.19, 248–254 (2006).
   PubMed Web of Science ®Google Scholar
• Duquette P, Pleines J, Girard M et al. The increased susceptibility of women to multiple sclerosis. Can. J. Neurol. Sci.19, 466–471 (1992).
   PubMed Web of Science ®Google Scholar
• Ghezzi A. Clinical characteristics of multiple sclerosis with early onset. Neurol. Sci.25, S336–S339 (2004).
   Google Scholar
• Hawkins SA, McDonnell GV. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J. Neurol. Neurosurg. Psychiatry67, 148–152 (1999).
   PubMed Web of Science ®Google Scholar
• Sloka JS, Pryse-Phillips WE, Stefanelli M. The relation between menarche and the age of first symptoms in a multiple sclerosis cohort. Mult. Scler.12, 333–339 (2006).
   PubMedGoogle Scholar
• Sadovnick AD, Yee IM, Ebers GC. Canadian Collaborative Study Group. Factors influencing sib risks for multiple sclerosis. Clin. Genet.58, 431–435 (2000).
   PubMed Web of Science ®Google Scholar
• Dwosh E, Guimond C, Sadovnik AD. Reproductive counselling for MS: a rationale. Int. MS J.10, 52–59 (2003).
   PubMedGoogle Scholar
• Kantarci OH, Barcellos LF, Atkinson EJ et al. Men transmit MS more often to their children vs women. Neurology67(2), 305–310 (2006).
   PubMed Web of Science ®Google Scholar
• Herrera BM, Ramagopalan SV, Orton S et al. Parental trasmission of MS in a population-based cohort Neurology69, 1202–1203 (2007).
   PubMedGoogle Scholar
• Mayr WT, Pittock SJ, McClellands RL et al. Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985–2000, Neurology61, 1373–1377 (2003).
   PubMed Web of Science ®Google Scholar
• Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain116, 117–134 (1993).
   PubMed Web of Science ®Google Scholar
• Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain126, 770–782 (2003).
   PubMed Web of Science ®Google Scholar
• Savettieri G, Messina D, Andreoli V et al. Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. J. Neurol.251, 1208–1214 (2004).
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Polman CH, Miller DH et al. Primary progressive multiple sclerosis. Brain120, 1085–1096 (1997).
   PubMed Web of Science ®Google Scholar
• Sumelahti ML, Tienari PJ, Wikstrom J et al. Survival of multiple sclerosis in Finland between 1964 and 1993. Mult. Scler.8, 350–355 (2002).
   PubMed Web of Science ®Google Scholar
• Orton S-M, Herrera B M, Yee IM et al. Canadian Collaborative Study Group sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol.5, 932–936 (2006).
   PubMed Web of Science ®Google Scholar
• Devonshire V, Duquette P, Dwosh et al. The immune system and hormones: review and relevance to pregnancy and contraception in women with MS. Int. MS J.10, 61–66 (2003).
   Google Scholar
• Robertson SA, Seamark RF, Gilbert LJ, Wegmann TG The role of cytokines in Gestation. Crit. Rev. Immunol.14, 239–292 (1994).
   PubMed Web of Science ®Google Scholar
• Confavreux C, Hutchinson M, Hours M. Pregnancy in multiple sclerosis group. Rate of pregnancy-related relapse in multiple sclerosis. N. Engl. J. Med.339, 285–291 (1998).
   PubMed Web of Science ®Google Scholar
• Delicostantinos G. Effects of prostaglandin E2 and progesterone in rat brain synaprosomal plasma membranes. Ciba Found. Symp.153, 190–205 (1990).
   PubMedGoogle Scholar
• Elenkov IJ, Wilder RL, Bakalov VK et al. 1L-2, TNF-α and hormonal changes during late pregnancy and hearly post-partum: implications for autoimmune disease activity during these times. J. Clin. Endocrinol. Metab.86, 4933–4938 (2001).
   PubMed Web of Science ®Google Scholar
• Zorgrager A, De Keyser J. The premestrual period and exacerbations in multiple sclerosis. Eur. Neurol.48, 204–206 (2002).
   PubMedGoogle Scholar
• Zordrager A, De Kayser J. Menstrually related worsening of symptoms in multiple sclerosis. J. Neurol. Sci.149, 95–97 (1997).
   PubMedGoogle Scholar
• Glesser B, Bergen R, Akporiaye E. Clinical status in multiple sclerosis does not change with the menstrual cycle. J. Neurol.246, 1–90 (1999).
   Google Scholar
• Pozzilli C, Falaschi P, Maniero C et al. MRI in multiple sclerosis during the menstrual cycle: relationship with sex hormone patterns. Neurology53, 622–624 (1999).
   PubMed Web of Science ®Google Scholar
• Tomassini V, Onesti E, Mainero C et al. Sex hormones modulate brain damage in multiple sclerosis: MRI evidence. J. Neurol. Neurosurg. Psychiatry76, 272–275 (2005).
   PubMed Web of Science ®Google Scholar
• van den Broek H, Damoiseaux J, De Baets MH, Hupperts R The influence of sex hormones on cytokines in multipla sclerosis and experimental autoimmune encephalomyelitis: a review. Mult. Scler.11, 349–359 (2005).
   PubMedGoogle Scholar
• Jansson L, Olsson T, Holmdahl R. Estrogen induces a potent suppression of experimental autoimmune encephalomyelitis and collagen-induced arthritis in mice. J. Neuroimmunol.53, 203–207 (1994).
   PubMedGoogle Scholar
• Liu HB, Loo KK, Palaszynski K et al. Estrogen receptor α mediates estrogen’s immune protection in autoimmune protection in autoimmune diseases. J. Immunol.171, 6936–6940 (2003).
   PubMedGoogle Scholar
• Palaszynski KM, Look KK, Ashouri JF et al. Androgens are protective in experimental autoimmune encephalomyelitis: implications for the multiple sclerosis. J. Neuroimunol.146, 144–152 (2004).
   PubMed Web of Science ®Google Scholar
• Smith R, Studd JW. A pilot study of the effect upon multiple sclerosis and menopause4, gormone replacement therapy and the mestrual cycle. J. R. Soc. Med.85, 612–613 (1992).
   PubMed Web of Science ®Google Scholar
• LeBlanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA285, 1489–1499 (2001).
   PubMed Web of Science ®Google Scholar
• Alonso A, Jick SS, Olek MJ et al. Recent use of oral contraceptives and the risk of multiple sclerosis. Arch. Neurol.62, 1362–1365 (2005).
   PubMed Web of Science ®Google Scholar
• Sicotte NL, Live SM, Klutch R et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann. Neurol.52, 421–428 (2002).
   PubMed Web of Science ®Google Scholar
• Hutchinson M. Oestrogen therapy for multiple sclerosis: not the way forward. Int. MS J.10(3), 98 (2003).
   PubMedGoogle Scholar
• Sicotte NL, Giesser BS, Tandon V et al. Testosterone treatment in multiple sclerosis: a pilot study. Arch. Neurol.64, 683–688 (2007).
   PubMed Web of Science ®Google Scholar
• Villard-Mackintosh L, Vessey MP. Oral contraceptives and reproductive factors in multiple sclerosis incidence. Contraception47, 161–168 (1993).
   PubMed Web of Science ®Google Scholar
• Thorogood M, Hannaford PC. The influence of oral contraceptives on the risk of multiple sclerosis. Br. J. Obstet. Gynaecol.105, 1296–1299 (1998).
   PubMedGoogle Scholar
• Herman MA, Hohol MJ, Olek MJ et al. Oral contraceptives and the incidence of multiple sclerosis Neurology55, 848–854 (2000).
   PubMedGoogle Scholar
• Cavalla P, Rovei V, Masera S et al. Fertility in patients with multiple sclerosis: current knowledge and future perspectives. Neurol. Sci.27, 231–239 (2006).
   PubMed Web of Science ®Google Scholar
• Runmarker B, Andersen O. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain118, 235–261 (1995).
   Google Scholar
• Cohen BA, Mikol DD. Mitoxantrone treatment of multiple sclerosis: safety considerations. Neurology63(Suppl. 6), S28–S32 (2004).
   PubMed Web of Science ®Google Scholar
• Marrosu MG, Musu L, Massole S et al. Effetti del mitoxantrone sulla fertilità nella sclerosi multipla – Studio FEMIMS (FErtility and Mitoxantrone In MS). Neurol. Sci.26, S27–S30 (2005).
   Google Scholar
• Ferrero S, Pretta S, Ragni N. Multiple sclerosis: management issues during pregnancy. Eur. J. Obstet. Gynecol. Reprod. Biol.115, 3–9 (2004).
   PubMed Web of Science ®Google Scholar
• Zaffaroni M, Ghezzi A. The prognostic value of age, gender, pregnancy and endocrine factors in multiple sclerosis. Neurol. Sci.2, S857–S860 (2000).
   Google Scholar
• Vukusic S, Hutchinson M, Hours M et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain127, 1353–1360 (2004).
   PubMed Web of Science ®Google Scholar
• DeSeze J, Chapelotte M, Delalande S et al. Intravenous corticosteroids in the post-partum period for reduction of acute exacerbations in multiple sclerosis. Mult. Scler.10, 596–597 (2004).
   PubMedGoogle Scholar
• Achiron A, Kishner I, Dolev M et al. Effect of intravenous immunoglobulin treatment of pregnancy and postpartum-related relapses in multiple sclerosis. J. Neurol.251, 1133–1137 (2004).
   PubMed Web of Science ®Google Scholar
• POPARTMUS study. Anounced at: ECTRIMS 2007. Prague, Czech Republic, 14–17 October, 2007.
   Google Scholar
• Dwosh E, Guimond C, Duquette P, Sadovnik AD. The interaction of MS and pregnancy: a critical review. Int. MS J.10, 38–42 (2003).
   PubMedGoogle Scholar
• Dahl J, Myhr KM, Daltveit AK et al. Pregnancy, delivery and birth outcome in women with multiple sclerosis Neurology65, 1961–1963 (2005).
   PubMed Web of Science ®Google Scholar
• Boskovic R, Wide R, Wolpin J et al. The reproductive effects of β interferon therapy in pregnancy: a longitudinal study. Neurology65, 807–811 (2005).
   PubMed Web of Science ®Google Scholar
• Portaccio E, Ghezzi A, Rizzo A et al. Pregnancy outcomes during therapy with interferon-β in patients with multiple sclerosis. Mult. Scler.S54 (2007).
   Google Scholar
• Nelson LM, Franklin GM, Jones MC. Risk of multiple sclerosis exacerbation during pregnancy and breast-feeding. JAMA259, 3441–3443 (1988).
   PubMed Web of Science ®Google Scholar
• Compston A. Coles A. Multiple sclerosis. Lancet359, 1221–1231 (2002).
   PubMed Web of Science ®Google Scholar
• Park-Wyllie L, Mazzotta P, Pastuszak A et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology62, 385–392 (2000).
   PubMedGoogle Scholar
• Tremlett HL, Oger J. Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian prospective. Mult. Scler.14(1), 94–105 (2008).
   PubMedGoogle Scholar
• Coyle PK. Gender issues. Neurol. Clin.23, 39–60 (2005).
   PubMed Web of Science ®Google Scholar
• Sandberg-Wollheim M, Frank D, Goodwin TM et al. Pregnancy outcomes during treatment with interferon β-1a in patients with multiple sclerosis. Neurology65(6), 802–806 (2005).
   PubMed Web of Science ®Google Scholar
• Temprano KK, Bandlamudi R, Moore TL. Antireumatic drugs in pregnancy and lactation. Semin. Arthritis Rheum.35, 112–121 (2005).
   PubMed Web of Science ®Google Scholar
• Ferrero S, Esposito F. Pretta S, Ragni N. Fetal risks related to treatment of multiple sclerosis during pregnancy and breastfeeding Expert Rev. Neurother.6, 1823–1831 (2006).
   PubMedGoogle Scholar
• De Santis M, Straface G, Cavaliere AF et al. The first case of mitoxantrone exposure in early pregnancy. Neurotoxicology28(3), 696–697 (2007).
   PubMedGoogle Scholar
• Kumar AR et al. Transfer of interferon a into human breast milk. J. Hum. Lact.16, 226–228 (2000).
   PubMedGoogle Scholar
• Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-β-1ain MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon- β-1a in secondary progressive MS: Clinical results. Neurology56, 1496–1504 (2001).
   PubMed Web of Science ®Google Scholar